Skip to main content

Fisher Healthcare to Distribute Verax Biomedical Platelet Bacterial Contamination Test in US

NEW YORK – Verax Biomedical said today that Fisher Healthcare will distribute its Platelet PGD Test in the US.

Under the exclusive agreement, Fisher Healthcare, a healthcare laboratory product distributor that is part of Thermo Fisher Scientific, will distribute the test through its channel. Further terms of the deal, including financial details, were not disclosed.

The Platelet PGD Test is designed to detect bacterial contamination in platelets and is used in a hospital transfusion service setting. It has a Safety Measure claim by the US Food and Drug Administration, allowing apheresis platelets in plasma to be used for up to seven days instead of five days.

Verax, which is based in Marlborough, Massachusetts, said it expects FDA guidance on bacterial risk mitigation strategies for platelets to come soon.

"We're extremely pleased that Fisher Healthcare will make our PGD Test available through its channel," said Verax CEO Jim Lousararian in a statement, adding that "this will dramatically increase our footprint in the US, allowing us to better serve our growing base of customers."

Previously, Verax's test was distributed by Fenwal/Freesnius Kabi, which focused on blood centers.